source
- Boehringer’s obesity drug cuts liver fat but lags behind competitors in weight lossData from a Phase 3 trial of Boehringer Ingelheim’s weekly injectable survodutide were presented at the American Diabetes Association meeting. Patients receiving the highest dose lost about 13% of…
- STAT roundup highlights obesity drug competition and other ADA conference updatesSTAT's ADA in 30 Seconds newsletter offers a brief snapshot of the American Diabetes Association's annual meeting, covering a range of topics for readers. Elaine Chen notes that the market for obe…